同步放化疗联合DC-CIK细胞生物治疗中晚期非小细胞肺癌的疗效

Effect of chemoradiation combined with DC-CIK cells biological therapy on the treatment of patients with middle-advanced non-small cell lung cancer

目的探讨同步放化疗联合DC-CIK细胞生物治疗中晚期非小细胞肺癌的疗效。方法 64例中晚期非小细胞肺癌患者分为试验组和对照组各32例,均采取放化疗方案进行治疗,试验组患者在对照组方案的基础上加用树突状细胞(DC)联合细胞因子诱导杀伤细胞(CIK)治疗。比较2组患者免疫指标及临床疗效。结果试验组患者的总缓解率为53.13%,显著高于对照组患者的21.86%(P<0.05);对照组患者的CD3^+、CD4^+及自然杀伤细胞百分比与观察组患者相比显著减低(P<0.05)。结论同步放化疗联合DC-CIK方案治疗中晚期非小细胞肺癌患者安全可靠。

Objective To explore the effect of chemoradiation combined with DC-CIK cells biological therapy on the treatment of patients with middle-advanced non-small cell lung cancer.Methods A total of 64 patients with middle-advanced non-small cell lung cancer were selected and divided into experimental group and control group,32 cases in each group. All patients were treated with chemoradiation schemes,and experimental group was given the DC-CIK cells biological therapy on the basis of the control group. The immune indexes and clinical effect were compared. Results The total remission rate of experimental group was 53. 13%,which was significantly higher than 21. 86% of the control group（ P〈 0. 05）. The levels of CD3＋,CD4＋ and the percentage of natural killer cells in the control group were significantly lower than those in the observation group（ P 〈0. 05）. Conclusion The chemoradiation combined with DC-CIK cells biological therapy is effective and reliable in the treatment of patients with middle-advanced non-small cell lung cancer.